Eris Lifesciences Limited has made the official transcript of its Analyst and Investor call publicly available. The call followed the announcement of the company’s financial results for the quarter and nine months ended December 31, 2025. The full document is accessible on the company’s investor relations website under the specified URL for transparency and detailed stakeholder review.
Disclosure of Q3 FY26 Earnings Call Transcript
Eris Lifesciences Limited formally informed the stock exchanges, BSE Limited and the National Stock Exchange of India Limited, regarding the publication of a significant corporate document. This document is the official TRANSCRIPT OF ANALYST AND INVESTOR CALL.
Context and Availability of Information
The call in question was convened subsequent to the announcement of the financial results covering the performance for the quarter ended December 31, 2025, and the cumulative nine-month period ending on the same date.
In compliance with transparency requirements, the complete transcript of the proceedings, including management commentary and subsequent Q&A sessions, has been made available to the public. Stakeholders, analysts, and investors can access this file directly via the investor section of the company’s website at the following URL: https://eris.co.in/financials/.
The file is specifically labeled internally as: Transcript of the Analyst and Investor Conference call Q3FY26.
Compliance Confirmation
The communication was authorized by Milind Talegaonkar, acting as the Company Secretary and Compliance Officer, and was dated 20 February 2026.
Source: BSE
